Cochrane · systematic review · CD009881
Progesterone receptor modulators for endometriosis
Fu, J, Song, H, Zhou, M, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 31.3%Low 8 · 50%Moderate 1 · 6.3%High 2 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Mifepristone versus placebo for endometriosis
Population: women with symptomatic endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prevalence of dysmenorrhoea Mifepristone vs placebo | OR 0.08 [0.04, 0.17] | 1 study · 352 participants | Moderate Downgraded: imprecision |
Prevalence of dyspareunia Mifepristone vs placebo | OR 0.23 [0.1, 0.51] | 1 study · 223 participants | Low Downgraded: imprecision |
Side effects: amenorrhoea Mifepristone vs placebo | OR 686.16 [92.29, 5101.33] | 1 study · 360 participants | High |
Side effects: hot flushes Mifepristone vs placebo | OR 28.79 [3.93, 210.73] | 1 study · 360 participants | High |
Gestrinone versus danazol for endometriosis
Population: women with symptomatic endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pelvic pain: none or mild Gestrinone vs danazol | OR 0.71 [0.33, 1.56] | 2 studies · 230 participants | Very low Downgraded: indirectness |
Dysmenorrhoea: none or mild Gestrinone vs danazol | OR 0.72 [0.39, 1.33] | 2 studies · 214 participants | Very low Downgraded: indirectness |
Dyspareunia: none or mild Gestrinone vs danazol | OR 0.83 [0.37, 1.86] | 2 studies · 222 participants | Very low Downgraded: indirectness |
Side effects: hirsutism Gestrinone vs danazol | OR 2.63 [1.6, 4.32] | 2 studies · 302 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Decreased breast size Gestrinone vs danazol | OR 0.62 [0.38, 0.98] | 2 studies · 302 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Side effects: hot flushes Gestrinone vs danazol | OR 0.79 [0.5, 1.26] | 2 studies · 302 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Side effects: acne Gestrinone vs danazol | OR 1.45 [0.9, 2.33] | 2 studies · 302 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Gestrinone versus leuprolin for endometriosis
Population: women with symptomatic endometriosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dysmenorrhoea, verbal rating scale Gestrinone vs leuprolin | no estimate extracted | 1 study · 55 participants | Low Downgraded: imprecision |
Dyspareunia, verbal rating scale Gestrinone vs leuprolin | no estimate extracted | 1 study · 52 participants | Low Downgraded: imprecision |
Amenorrhoea Gestrinone vs leuprolin | OR 0.04 [0.01, 0.38] | 1 study · 49 participants | Low Downgraded: imprecision |
Spotting or bleeding Gestrinone vs leuprolin | OR 22.92 [2.64, 198.66] | 1 study · 49 participants | Low Downgraded: imprecision |
Side effects: hot flushes Gestrinone vs leuprolin | OR 0.2 [0.06, 0.63] | 1 study · 55 participants | Low Downgraded: imprecision |